Contact Us:
• info@biofluidica.com
January 17, 2021
M.U. is a 32-year-old G2 P1 Caucasian female, who presented at 13 weeks’ gestation by LMP for first trimester combined screening. The crown-to-rump length measurement was consistent with 11 weeks’ gestation. The fetal body was noted to be small in comparison to the head and there was suspicion for ventriculomegaly. The placenta was noted to be thin. The patient was offered chorionic villus sampling (CVS) due to the increased suspicion of digynic triploidy. She declined CVS at this time but did agree to have NIPS performed. NIPS was reported as “high-risk due to low fetal DNA fr action” but was otherwise uninformative. The patient had a transcervical CVS performed two weeks later without complications.
January 17, 2019
NEW YORK (GenomeWeb) – Fresh off being awarded several grants by the National Institutes of Health, startup BioFluidica has begun three different clinical studies to detect exosomes, cell-free DNA, and rare cells in patients' bloodstreams to identify acute lymphoblastic leukemia (ALL) and other cancer-related diseases.
The San Diego, California-based startup is also exploring the use of its Liquid Scan platform in the non-invasive prenatal testing space by extracting and detecting neonatal cells from a mother's bloodstream.
April 1, 2019
BioFluidica presented at the AACR Conference in Atlanta, GA, April 2019 the following abstracts, "A Non-invasive Diagnostics to Detect Circulating Leukemic Cells in Blood. A microfluidic platform to monitor MRD in Leukemic patients" and "Automated Microfluidic Platform Allows for Interrogation of Tumor Biomarkers from Whole Blood."
March 12, 2019
San Diego, California-based BioFluidica Inc. developed the Liquid Scan microfluidic chip that can both monitor and detect circulating tumor cells through a simple blood test.
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA.
March 10, 2019
BioFluidica presented at the Molecular Med Tri-Conference in San Francisco, CA, March 2019 the following abstracts, "Detection of CTCs from Whole Blood of Lung Cancer Patients Using Automated Liquid Scan Microfluidic Chip Technology" and "Isolation of Cancer Cell-Derived Extracellular Vesicles Utilizing an Automated Microfluidic Platform".
January 20, 2019
Tune in February 20, 2019 as KU Cancer Center director Roy Jensen, MD, will host Steven Soper, PhD, KU Cancer Center researcher and University of Kansas School of Engineering foundation distinguished professor in the departments of Chemistry and Mechanical Engineering, as well as Andrew Godwin, PhD, deputy director of KU Cancer Center. They will discuss how cancers can be detected earlier using precision medicine tools.
For more information or to sign up:
November, 2018
BioFluidica presented at the Prenatal Diagnostics Conference in Boston, MA, November 2018 the following abstract titled "A Microfluidic Platform to Capture & Detect Trophoblastic Fetal Cells from Maternal Blood for Noninvasive Prenatal Screening".
January 07, 2019
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded two separate SBIR Phase I NIH grants, the first in support of "Parallel and high throughput isolation of cancer cell derived extracellular vesicles," and the second in support of "Parallel and high throughput isolation of cfDNA to target detection of rare, highly conserved nucleotide polymorphisms."
"We are excited to expand our technology to be able to capture not only circulating cancer cells from solid tumor and blood cancers but also now to begin to isolate cfDNA and exosomes, as well," said Rolf Muller, BioFluidica's CEO. "We can now employ all important biomarkers on one single liquid biopsy platform, our programmable microfluidic chips. This will have very positive outcomes for personalized medicine in the cancer diagnostics space as we commercialize further, as well as for researchers and patients."
January 10, 2019
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of "Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia."
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood and accounts for approximately 30% of all cancers diagnosed before the age of 18 years. The primary cause of death for ALL patients is disease relapse. Therefore, monitoring for minimal residual disease (MRD) is considered the most powerful predictor of outcome in acute leukemias.
August 31, 2018
Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up chemicals, cell fragments and whole cells. But signs of disease may be exceedingly rare, and reliably picking them out has spawned an industry devoted to the task.
La Jolla’s BioFluidica says it has greatly improved upon existing technology with its own method to find circulating cancer cells. which it is testing in leukemia patients. The goal is to replace invasive and painful bone marrow biopsies for detecting when the cancer reoccurs.
May 16, 2018
SAN DIEGO, May 16, 2018 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study to replace painful bone marrow biopsies through a simple blood test for Acute Myeloid Leukemia. The larger study sponsored by a $1.5 million Phase 2 Award from Small Business Innovation Research enrolls and tracks 40 patients with Acute Myeloid Leukemia, a type of cancer of the blood and bone marrow, in a one-year pilot study to search for minimal residual disease (cancer cells undetected after treatment) and for possible onset of relapse following therapy.